Detail akcie Vaxil Bio Rg online

Business Summary: Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Vaxil Bio Ltd revenues was not reported. Net loss applicable to common stockholders excluding extraordinary items decreased 66% to C$54K. Lower net loss reflects Financial income increase from C$8K to C$89K (income), General and administration costs - Balan decrease of 53% to C$68K (expense), Research and development decrease of 60% to C$4K (expense).